Cancer Doctors Join Insurers in U.S. Drug-Cost Revolt
This article is for subscribers only.
The backlash over surging drug prices is starting to take hold.
With the average cost of branded cancer drugs doubling over the past decade to about $10,000 per month in the U.S., doctors, insurers and politicians are all moving in different ways to pressure drugmakers on pricing.